PreludeDx ® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results